Literature DB >> 31625025

Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.

Yuan-Yuan Shang1, Nan Yu1, Li Xia1, Ying-Yao Yu1, Chun-Mei Ma1, Ya-Ning Jiao1, Yun-Feng Li2, Yuan Wang1, Jie Dang3, Weichao Li4.   

Abstract

Previous evidence has shown that the increased expression of aurora kinase is closely related to melanoma progression and is an important therapeutic target in melanoma. Danusertib is an inhibitor of aurora kinase, and recent studies have shown that danusertib treatment induces autophagy in several types of cancer. Interestingly, autophagy plays a dual function in cancer as a pro-survival and anti-survival factor. In this study, we investigated the role of danusertib on the induction of autophagy in melanoma and determined the impact of autophagy induction on its anticancer activity against melanoma. Our results showed that danusertib can significantly inhibit melanoma growth by inducing cell cycle arrest and apoptosis. In addition, we demonstrated that danusertib treatment significantly inhibits the oncogenic Akt/mTOR signaling pathway and induces autophagy in melanoma cells. Furthermore, we identified that the inhibition of autophagy can enhance the inhibitory effects of danusertib on melanoma growth. Thus, the induction of autophagy by danusertib appears to be a survival mechanism in melanoma cells that may counteract its anticancer effects. These findings suggest a novel strategy to enhance the anticancer efficacy of danusertib in melanoma by blocking autophagy.

Entities:  

Keywords:  Akt/mTOR; Aurora kinase; Autophagy; Danusertib; Melanoma

Year:  2020        PMID: 31625025     DOI: 10.1007/s13346-019-00668-5

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  23 in total

Review 1.  Autophagy fights disease through cellular self-digestion.

Authors:  Noboru Mizushima; Beth Levine; Ana Maria Cuervo; Daniel J Klionsky
Journal:  Nature       Date:  2008-02-28       Impact factor: 49.962

2.  miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A.

Authors:  Xiao Chang; Haiping Zhang; Shi Lian; Wei Zhu
Journal:  Biochem Biophys Res Commun       Date:  2016-05-24       Impact factor: 3.575

3.  Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Authors:  Ilana Chefetz; Jennie C Holmberg; Ayesha B Alvero; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

4.  Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Authors:  Caroline Bonet; Sandy Giuliano; Mickaël Ohanna; Karine Bille; Maryline Allegra; Jean-Philippe Lacour; Philippe Bahadoran; Stéphane Rocchi; Robert Ballotti; Corine Bertolotto
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

5.  Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation.

Authors:  R Rong; L Y Jiang; M S Sheikh; Y Huang
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

6.  Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.

Authors:  Altaf A Dar; Alexander Zaika; Maria B Piazuelo; Pelayo Correa; Tatsuki Koyama; Abbes Belkhiri; Kay Washington; Antoni Castells; Manuel Pera; Wael El-Rifai
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

Review 7.  Autophagy in the pathogenesis of disease.

Authors:  Beth Levine; Guido Kroemer
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

8.  Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Authors:  Yan Liu; Oriana E Hawkins; Yingjun Su; Anna E Vilgelm; Tammy Sobolik; Yee-Mon Thu; Sara Kantrow; Ryan C Splittgerber; Sarah Short; Katayoun I Amiri; Jeffery A Ecsedy; Jeffery A Sosman; Mark C Kelley; Ann Richmond
Journal:  EMBO Mol Med       Date:  2012-11-25       Impact factor: 12.137

9.  The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Authors:  Nina Fenouille; Mélanie Tichet; Maeva Dufies; Anaïs Pottier; Ariane Mogha; Julia K Soo; Stéphane Rocchi; Aude Mallavialle; Marie-Dominique Galibert; Amir Khammari; Jean-Philippe Lacour; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

10.  Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.

Authors:  Dan Zi; Zhi-Wei Zhou; Ying-Jie Yang; Lin Huang; Zun-Lun Zhou; Shu-Ming He; Zhi-Xu He; Shu-Feng Zhou
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

View more
  3 in total

1.  Gelatine nanostructured lipid carrier encapsulated FGF15 inhibits autophagy and improves recovery in spinal cord injury.

Authors:  Yibo Ying; Guangheng Xiang; Min Chen; Jiahui Ye; Qiuji Wu; Haicheng Dou; Sunren Sheng; Sipin Zhu
Journal:  Cell Death Discov       Date:  2020-12-02

Review 2.  Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.

Authors:  Naheed Arfin Borah; Mamatha M Reddy
Journal:  Molecules       Date:  2021-04-01       Impact factor: 4.411

3.  The new horizon of biomarker in melanoma patients: A study based on autophagy-related long non-coding RNA.

Authors:  Zhehong Li; Junqiang Wei; Honghong Zheng; Yafang Zhang; Mingze Song; Haiying Cao; Yu Jin
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.